Drugs

Natural Essentials, Inc.

FDA issued a warning letter to Natural Essentials, Inc. (Streetsboro, OH, United States) on Nov 10, 2026, citing 21 CFR 211.192, 21 CFR 211.160, 21 CFR 211.84 and 21 CFR 211.194. Subject: CGMP, Finished Pharmaceuticals, Adulterated, OTC.

From the letter: “Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).”

Streetsboro, OH, United StatesIssued Nov 10, 2026Posted Nov 17, 2026No close-out recorded

At a glance

What a reviewer notes before reading: findings, citations, the response deadline and what the letter warns of.

Violations
4 findings · 4 issue types
Response due
Fifteen (15) business days of receipt
FDA asks for
8 actions
Named as possible actions
Seizure, injunction
Issued by
Center for Drug Evaluation and Research
Published status
No close-out recorded

AI assisted findings

Model-assisted reading of each issue. Open one to see the FDA text it comes from, and check it against the full letter.

01Investigations & OOS · 21 CFR 211.192OOS and OOL results were not thoroughly investigated; lots were released based on passing retests without scientific justification.
Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).
02Laboratory controls & testing · 21 CFR 211.160(b)Laboratory controls were inadequate because specifications exceeded USP limits and microbiological test methods were not validated.
Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).
03Components & suppliers · 21 CFR 211.84(d)(1)Incoming components, including the active ingredient, were not adequately tested for identity and hazardous impurities.
Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).
04Records & data integrity · 21 CFR 211.194(a)Laboratory records were incomplete because processed chromatograms were not retained and spreadsheets were uncontrolled.
Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).

Additional FDA passages

3 extracted findings

Selected FDA passages, not the complete letter.

01

You failed to adequately investigate multiple out-of-specification (OOS) and out-of-limit (OOL) results from your drug component and over-the-counter (OTC) drug product testing. For example:

02

You failed to perform adequate identity testing of each incoming lot of **(b)(4)** used as a component in the manufacture of your OTC **(b)(4)** drug products. For example, you failed to adequately test your incoming **(b)(4)**, used as an active ingredient, for **(b)(4)**.

03

You failed to exercise appropriate controls over your computerized systems. During the inspection, you admitted to preserving raw chromatographic data but failing to retain the processed chromatograms.

What FDA requested

  • A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including for each OOS: determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error; for investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation; for all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history) and provide a summary of potential manufacturing and testing root causes for each investigation, and any manufacturing operation improvements.
  • A comprehensive review and remediation plan for your OOS and OOL result investigation systems. The CAPA should include, but not be limited to, addressing the following: Quality unit oversight of laboratory investigations; Identification of adverse laboratory control trends; Resolution of causes of laboratory variation; Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified; Adequate scoping of each investigation and its CAPA; Revised OOS investigation procedures with these and other remediations; A similar review and remediation of your system for handling OOL findings (i.e., data that falls outside action limits).
  • A detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.
  • A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.
  • A comprehensive evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA, including but not limited to: a comprehensive retrospective evaluation review of each test method to determine any inadequacies, including but not limited to those cited in this letter; where a method is found unsuitable for its intended use (e.g., inadequate capacity to enumerate), provide information on a new suitable method that will be employed; improved systems to ensure selection and suitability of microbiological test methods in future before implementation; once this full evaluation is complete, provide all findings, data, and deviations encountered.
  • Following review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.
  • Updated analytical procedures, including confirmatory testing and speciation, that ensure regulatory compliance for all microbiological testing. This should also include an explanation of whether sample preparations are reserved to assist in conducting OOS investigations.
  • A thorough remediation plan to operate a suitable (b)(4) system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces (b)(4) adhering to (b)(4), USP, monograph specifications and appropriate microbial limits.

FDA Warning Letter

71 paragraphs · 7 sections

Text as published on FDA.gov, retrieved Nov 18, 2026. Layout added for reading; the wording is FDA’s. View on FDA.gov (opens in a new tab)

DatedNovember 10, 2026
Reference320-27-22
AddressedMr. Gary L. Pellegrino

1Introduction

1 paragraph

This warning letter advises you of significant violations observed during a United States Food and Drug Administration (FDA) inspection of your facility and provides you the opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.

2FDA Inspection

4 paragraphs

Violations were observed and documented during an inspection of your drug manufacturing facility, Natural Essentials Inc., FDA Establishment Identifier (FEI) 1520307, at 10375 State Route 43, Streetsboro, from June 22 to 26, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.

This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).

Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).

We reviewed your August 11, 2026, response to our Form FDA 483 in detail.

3Violations of the Federal Food, Drug, and Cosmetic Act

31 paragraphs

The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.

1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).

You failed to adequately investigate multiple out-of-specification (OOS) and out-of-limit (OOL) results from your drug component and over-the-counter (OTC) drug product testing. For example:

Your (b)(4) assay result for (b)(4) Lot (b)(4) drug product exceeded the (b)(4)% specification limit, and retesting confirmed the OOS result. Instead of rejecting the entire lot, you released most of the lot based on passing results obtained from additional limited sampling which did not ensure all drug products released met your (b)(4) assay specification. Your practice of rejecting a partial drug product batch is an indication that your firm does not have well-controlled manufacturing and release procedures.

Between 2025 and 2026, you conducted several investigations into microbial growth detected during your drug product final release testing. You did not identify the recovered microorganisms. These investigations did not conclusively establish root cause(s) for the failing results. Nevertheless, you released the affected lots based on passing retest results, invalidating the original failing results without scientific justification.

Between 2024 and 2026, you conducted multiple OOS and out-of-limit (OOL) investigations for (b)(4) samples that exceeded (b)(4), and microorganism limits. These investigations did not consider whether your (b)(4) system was adequately validated to ensure it consistently produces (b)(4) meeting (b)(4) United States Pharmacopeia (USP) monograph specifications and appropriate microbial limits. FDA’s 2023 inspection noted incomplete validation of your (b)(4) system and inadequate investigations into microbial recoveries, including (b)(4), in your (b)(4) samples.

Passing retest results alone cannot serve as the basis for invalidating OOS results. As a manufacturer, you have a responsibility to fully investigate failing chemical and microbial test results that may impact drug product quality.

In your response, you attribute the (b)(4) of (b)(4) in (b)(4) Lot (b)(4) to inadequate (b)(4) time. You revised your (b)(4) procedures and retrained personnel. You acknowledge that (b)(4) failures were not investigated. You initiated a retrospective (b)(4) excursion assessment, revised your investigation procedures to require documentation of (b)(4) investigations, and incorporated (b)(4) data into your (b)(4) system monitoring program. Additionally, you revised your OOS procedure to strengthen investigations requirements for laboratory testing errors and to require documented scientific justification and quality unit approval prior to invalidating any OOS result.

Your response is inadequate. The scope and criteria of your retrospective batch review is undefined, and your sampling strategy remains scientifically unjustified. You lack a risk assessment for the more than (b)(4) units of (b)(4) Lot (b)(4) that were released despite the unresolved investigation conclusion. You do not establish the relationship between (b)(4) and (b)(4) time. Additionally, you lack a retrospective risk assessment of finished drug product lots released with inappropriately invalidated microbial test results. You do not describe how you plan to ensure that your laboratory investigations are robust and clearly identify potential sources of contamination.

Further, you do not identify root cause(s) for the (b)(4), and microbial contamination failures, nor do you provide details of your interim controls in place to ensure product quality while corrective actions and preventive actions (CAPA) are ongoing.

It is essential to conduct thorough, well documented, and scientifically sound investigations to identify root causes of OOS results, evaluate all potentially affected batches, and implement timely and effective CAPA plans. Whenever an investigation lacks conclusive evidence of laboratory error, a thorough investigation of potential manufacturing causes must be performed.

For more information about handling failing, OOS, or other unexpected results and documentation of your investigations, see FDA’s guidance document Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production at https://www.fda.gov/media/158416/download. While this guidance addresses chemistry laboratory analyses, many of its principles are also relevant to investigating OOS microbiological results and OOT results.

In response to this letter, provide:

A retrospective, independent review of all invalidated OOS (including in-process and release/stability testing) results for U.S. products for the last three years from the initial date of inspection and a report summarizing the findings of the analysis, including the following for each OOS:o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment/facilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing and testing root causes for each investigation, and any manufacturing operation improvements.

A comprehensive review and remediation plan for your OOS and OOL result investigation systems. The CAPA should include, but not be limited to, addressing the following:o Quality unit oversight of laboratory investigationso Identification of adverse laboratory control trendso Resolution of causes of laboratory variationo Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identifiedo Adequate scoping of each investigation and its CAPAo Revised OOS investigation procedures with these and other remediationso A similar review and remediation of your system for handling OOL findings (i.e., data that falls outside action limits)

A detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution or within expiry. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.

2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).

(b)(4) Specifications

Your (b)(4) specification limit for (b)(4) (e.g. not more than (b)(4) parts per million) exceeded the (b)(4) USP monograph specification limit (e.g., not more than (b)(4) parts per million). The review of your (b)(4) OOS investigations conducted between 2024 and 2026 documented (b)(4) measurements as high as (b)(4) ppm.

In your response, you acknowledge your internal (b)(4) specification deviated from the USP <(b)(4)> requirements and state that a third-party evaluation confirmed your (b)(4) system can meet the USP specification. You commit to revising your standard operating procedure to align acceptance criteria with USP <(b)(4)>, updating your validation, and revising (b)(4) investigation procedures.

Your response is inadequate. You do not provide a risk assessment of drug products manufactured using (b)(4) that did not meet USP specifications. You also do not provide data demonstrating that your (b)(4) system is adequately validated to ensure your (b)(4) system will consistently produce (b)(4) that is appropriate for pharmaceutical use and meets the USP monograph for (b)(4). Further, you do not describe any interim controls in place to ensure product quality while you revalidate your (b)(4) system.

Microbial Test Methods

You use the (b)(4) for microbiological testing of your finished drug products (e.g., total aerobic microbial count and total yeast and mold counts). You failed to demonstrate that this (b)(4) test method is equivalent to or better than USP compendial methods and suitable for its intended use. Additionally, you did not align your procedure’s incubation times and temperature specifications with USP <61> specifications.

The (b)(4) microbiological testing methodology uses qualitative pass/fail criterion that does not ensure appropriate quantitative enumeration results. The method is inadequate because it does not provide sufficient data on contamination levels, which is essential for trend analysis and evidence-based risk assessment to support quality evaluations and patient safety. Further, this system does not meet the minimum requirements for adequate identification of specified and objectionable microorganisms. Consequently, you are unable to perform speciation of the microbial contaminants recovered from the affected finished drug product lots.

Test methods must be validated to demonstrate they are suitable for their intended use, reproducible, equivalent or superior to applicable USP compendial methods, and capable of detecting the presence of objectionable microorganisms in each component or finished drug product.

In response to this letter, provide:

A comprehensive independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.

A comprehensive evaluation of microbiological tests methods used to perform total counts and identification to evaluate suitability for intended use, followed by systemic CAPA, including but not limited to:o A comprehensive retrospective evaluation review of each test method to determine any inadequacies, including but not limited to those cited in this letter.o Where a method is found unsuitable for its intended use (e.g., inadequate capacity to enumerate), provide information on a new suitable method that will be employedo Improved systems to ensure selection and suitability of microbiological test methods in future before implementation.o Once this full evaluation is complete, provide all findings, data, and deviations encountered.

Following review by an independent third-party, provide updated validation protocols and final reports that adequately address methods for each product, including specificity, limit of detection, robustness, ruggedness, and repeatability. This should include an evaluation of whether sample sizes are appropriate. Where you intend to use non-compendial methods, provide studies evaluating the equivalence or superiority of the method to the USP method.

Updated analytical procedures, including confirmatory testing and speciation, that ensure regulatory compliance for all microbiological testing. This should also include an explanation of whether sample preparations are reserved to assist in conducting OOS investigations.

A thorough remediation plan to operate a suitable (b)(4) system. Include a robust ongoing control, maintenance, and monitoring program to ensure the remediated system consistently produces (b)(4) adhering to (b)(4), USP, monograph specifications and appropriate microbial limits.

43. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).

9 paragraphs

You failed to perform adequate identity testing of each incoming lot of (b)(4) used as a component in the manufacture of your OTC (b)(4) drug products. For example, you failed to adequately test your incoming (b)(4), used as an active ingredient, for (b)(4).

Identity testing of high-risk drug components, such as (b)(4), includes limit tests in the USP to ensure that the component meets the relevant safety limits for (b)(4) levels. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects hazardous impurities, you failed to ensure the acceptability of these components for use in the manufacture of your drug products.

In your response, you identify several drug products that contain (b)(4) and commit to testing reserve samples to confirm the absence of (b)(4) contamination. You also commit to working with a third-party laboratory to develop an in-house method to test for the presence of (b)(4) in (b)(4).

Your response is inadequate. You do not commit to implementing routine USP monograph identity testing requirements for (b)(4), which includes a limit test for (b)(4), nor do you provide test results for reserve samples of (b)(4) containing drug products. Furthermore, you do not evaluate other components used to manufacture your drug products for compliance with all applicable USP monograph identity requirements.

The use of (b)(4) contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4)

In response to this letter, provide:

The chemical and microbiological quality control specifications you use to test and release each incoming lot of components for use in manufacturing.

A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. Include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of (b)(4) of the USP monograph.

A commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of components within expiry of manufactured drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).

54. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards (21 CFR 211.194(a)).

7 paragraphs

You failed to exercise appropriate controls over your computerized systems. During the inspection, you admitted to preserving raw chromatographic data but failing to retain the processed chromatograms.

Additionally, you lacked adequate controls for the spreadsheets and documents used for CGMP data entry, review, and retention. During the inspection, our investigator identified several uncontrolled and unlocked worksheets containing CGMP trending data for the (b)(4) system, leaving the data vulnerable to alteration or deletion.

In your response, you commit to developing an electronic records control procedure, restricting unauthorized modification of spreadsheets used for CGMP data processing, and initiating a retrospective data integrity assessment. You established interim measures, including independent analyst and quality unit review of processed chromatograms prior to disposition, and evaluating your chromatographic software for enhanced data retention and audit trail capability.

Your response is inadequate. You do not explain how your retrospective assessment will comprehensively identify data integrity and control gaps. This is concerning because post-analysis modifications prevent the reconstruction of previously processed chromatograms. You also do not explain how you will validate your spreadsheets to ensure formulas are accurate and secure from manipulation. Additionally, you provide no timelines for finalizing procedures or completing your chromatography software evaluation and validation.

In response to this letter, provide:

A comprehensive assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.

An updated validation for your chromatography peak processing method and evidence that the processed chromatograms are retained within the computer system.

6CGMP Consultant Recommended

2 paragraphs

Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.

Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.

7Conclusion

4 paragraphs

You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.

Unresolved violations may prevent other Federal agencies from awarding contracts. Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.

Response requested

Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your written response with FEI 1520307 and ATTN: Christopher Keating in the subject line of the email.

FDA posts warning letters to www.FDA.gov.

Sincerely,/S/

Francis GodwinDirectorOffice of Manufacturing QualityOffice of ComplianceCenter for Drug Evaluation and ResearchU.S. Food and Drug Administration

______________________

1 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.

Citations and trends

Each 21 CFR section, ISO 13485 clause and issue type in this letter, how often it appears across all letters, and its trend by the year FDA issued the letters. 2026 runs to Nov 10, 2026, compared with the same dates last year. Select a row or a bar to see those letters in Letters. As cited in this historical letter, not a statement of current requirements.

Regulations

Also cited: 21 CFR 210

Issue types

Investigations & OOSAI-assigned issue type202letters1finding here
49 letters issued this year vs 35 by the same date last year · +40%

Record details

Issuing center
Center for Drug Evaluation and Research
Issuing office
Center for Drug Evaluation and Research
Location
Streetsboro, OH, United States
Letter posted date
Nov 17, 2026
Letter issue date
Nov 10, 2026
Addressed to
President
Inspection dates
Jun 22, 2026
Response window
15 business days after receipt of this letter
Read the source clause
Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter.
Record length
2,985 words · 78 recorded redactions
Published status
No published close-out
FDA reference
320-27-22
Original letter
View on FDA.gov (opens in a new tab)
Dataset last checked
Nov 19, 2026 · How this is built

A response window is not a calculated due date. Source excerpts are selected passages. Finding interpretations and categories are model-assisted. Verify the original letter before relying on a finding.

See the pattern across 1,711 lettersFind letters like this →
Keep exploring

More drug letters

Recent records for the same product type. Your previous filters remain available when you return.

Keep exploring

Find letters like this →
For regulated teams

Put this kind of reading to
work on your own records.

Botable builds and runs a custom AI layer around the software you already use, so your team can do the job you hired them for.

Every letter by dateHow this database is built

FDA Warning Letter Alerts

Share this view

Send the same filters, search and view to a colleague.

You choose what to post or send. Sharing a link does not change access to this site.